Anandamide Attenuates Th-17 Cell-Mediated Delayed-Type Hypersensitivity Response by Triggering IL-10 Production and Consequent microRNA Induction

Austin R. Jackson, Prakash Nagarkatti, Mitzi Nagarkatti*

Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States of America

Abstract
Endogenous cannabinoids [endocannabinoids] are lipid signaling molecules that have been shown to modulate immune functions. However, their role in the regulation of Th17 cells has not been studied previously. In the current study, we used methylated Bovine Serum Albumin (mBSA)-induced delayed type hypersensitivity [DTH] response in C57BL/6 mice, mediated by Th17 cells, as a model to test the anti-inflammatory effects of endocannabinoids. Administration of anandamide [AEA], a member of the endocannabinoid family, into mice resulted in significant mitigation of mBSA-induced inflammation, including foot pad swelling, cell infiltration, and cell proliferation in the draining lymph nodes [LN]. AEA treatment significantly reduced IL-17 and IFN-γ production, as well as decreased RORγt expression while causing significant induction of IL-10 in the draining LNs. IL-10 was critical for the AEA-induced mitigation of DTH response inasmuch as neutralization of IL-10 reversed the effects of AEA. We next analyzed miRNA from the LN cells and found that 100 out of 609 miRNA species were differentially regulated in AEA-treated mice when compared to controls. Several of these miRNAs targeted proinflammatory mediators. Interestingly, many of these miRNA were also upregulated upon in vitro treatment of LN cells with IL-10. Together, the current study demonstrates that AEA may suppress Th-17 cell–mediated DTH response by inducing IL-10 which in turn triggers miRNA that target proinflammatory pathways.

Introduction
Cannabinoids are compounds derived from the Cannabis sativa plant and exert many effects on the immune system [1,2,3]. Cannabinoids have potential as therapeutic agents in several different disease conditions, including experimental autoimmune hepatitis, Multiple Sclerosis, and Graft vs. Host Disease [1,2–5]. In addition, there is an endogenous network of cannabimimetic lipids called the endogenous cannabinoid system that serve as signaling molecules regulating many processes in the Central Nervous System. The major members of this family of compounds include Arachidonyl Ethanolamide [AEA, Anandamide] and 2-Arachidonyl Glycerol [2-AG]. These compounds act by activating specific receptors called cannabinoid receptors, of which there are two, CB1 and CB2. The CB receptors are members of the G-Protein coupled receptor family and mediate their effects through a series of G proteins and adaptors [6]. While endocannabinoids are most concentrated in the central nervous system, they also mediate peripheral effects. Among these, changes in the endocannabinoid system have been reported in liver injury [7], colitis [8], and diabetes [9]. When both cannabinoid receptors were knocked out, mice were more prone to developing allergic hypersensitivity [10]. This report suggested a role of the endogenous cannabinoid system in regulation of allergic inflammation.

Methylated Bovine Serum Albumin [mBSA] induces a Type-IV delayed-type hypersensitivity [DTH] characterized predominantly by Th17-driven inflammation and swelling at the site of antigen rechallenge [11]. This model of hypersensitivity has been used as a way to study the development of Th17 cells in vivo by injecting both intra-articularly into mice to induce arthritis [12] as well as subcutaneously to sensitize, and rechallenge the animals in the footpads [13] or the ear to induce DTH[14]. Th17 cells, besides their role in microbial immunity, are directly involved in the pathogenesis of autoimmune diseases such as arthritis [15], Experimental Autoimmune Encephalomyelitis [EAE] [16,17], and myocarditis [18]. Thus, Th17 cells are a target for pharmaceutical intervention because they promote a pro-inflammatory environment.

MicroRNAs are a class of small nucleic acids ranging 19–25 nucleotides long that have an important function regulating expression of genes [19–22]. These small RNA species regulate expression of genes by complementary base-pairing in the 3’ UTR of expressed miRNA and alter the stability of the targeted mRNA [23,24]. Many studies have shown the effect of miRNAs on T helper cell differentiation, including the effect of let-7e on Th1/Th17 differentiation in EAE [25], miRNA 155 on Th17 differentiation [26], and miR10a induced by TGF-β that inhibits the plasticity of T cell subsets [27]. miRNA regulation in airway inflammation and asthma has also been described [28]. Moreover, miRNA 21 has been shown to be important for chemical-induced hypersensitivity [29]. However, there are no studies showing how
miRNA can regulate IL-17-mediated DTH reaction or endocannabinoid-mediated immunosuppression.

In this study, we show that treatment with AEA can attenuate mBSA-induced hypersensitivity through secretion of IL-10 involving miRNA that target IL-17 and other proinflammatory pathways. These studies not only help understand the mechanism of action of endocannabinoids but also shed light on potential therapeutic targets against inflammatory disorders.

**Materials and Methods**

**Reagents**
AEA was obtained from the National Institute on Drug Abuse [NIDA], National Institutes of Health [Bethesda, MD]. Methylated BSA [mBSA] and Freund’s Complete Adjuvant [CFA] was purchased from Sigma Aldrich, CD3-Phycoerythrin-Cydan 7[PE-Cy7], CD4-PE, and IL17A FITC, monoclonal antibody was purchased from Biolegend. Annexin V-PI staining kit was purchased from biolegend. Complete RPMI was made according to the following formulation: 1% Penicillin/Streptomycin, 10% Fetal bovine Serum, 20 mM Glutamine, 50µM ß-Mercaptopethanol, and 10 mM HEPES.

**Mice**
Female adult C57Bl/6 mice were purchased from National Cancer Institute, National Institute of Health [Frederick, MD] and bred under appropriate conditions. All protocols were approved by the University of South Carolina Institutional Animal Care and Use Committee [IACUC] and mice were housed under specific pathogen-free conditions.

**Induction of mBSA-Induced Type-IV hypersensitivity and AEA treatment**
Groups of 5 Mice were sensitized to mBSA by giving a subcutaneous injection of 150 µg mBSA emulsified in CFA, as described previously [15]. Two injections were given to each mouse, one in each hind flank. After 6 days, mice were rechallenged in the right footpad with 200 µg mBSA in PBS and in the left footpad with PBS only. Percent increase in swelling was determined by the following equation: [(thickness of mBSA footpad thickness of PBS footpad)/thickness of PBS footpad] × 100%. Mice were treated with either 40 mg/kg body weight AEA or vehicle, as described before [1] for 2 days prior to rechallenge. Mice were sacrificed 24 hours after rechallenge.

**Th17 intracellular stain**
Cells were isolated from the draining lymph nodes [LN] 24 hours after mBSA rechallenge. These cells were stained for IL-17A using Intracellular Cytokine Staining Kit [BD biosciences] per manufacturer’s specifications. Briefly, cells were first stained for CD4-PE and then fixed/permeabilized. Next, the cells were stained for IL-17A-FTTC and analyzed on an FC500 Cytometer.

**Histology**
Footpads from AEA-treated and vehicle-treated mice were isolated for histological examination. The feet were cut distal to the ankle and decalcified/fixed in Cal-Rite [Fisher scientific]. The slides were stained with H&E for generic architecture and immune cell infiltration.

**In Vitro mBSA restimulation**
Mice were sensitized to mBSA as described above, but sacrificed on day 6. Cells were isolated from LN, plated at 1×10⁶ cells/well, cultured in the presence of 40 µg/ml mBSA, and treated with either vehicle or AEA.

**Cytokine Analysis**
Cells from the LN of mBSA-sensitized mice were prepared as before and cultured overnight without mBSA to analyze for spontaneous cytokine secretion. Next, culture supernatants were analyzed for pro-inflammatory cytokines IL-17, IFN-γ, and IL-10 using ELISA kit per manufacturer’s specifications [Biolegend].

**miRNA array and analysis**
miRNA analysis was performed as described previously [27]. Total RNA was isolated from draining LNs from vehicle-treated and AEA-treated mice by using the miRNAeasy total RNA isolation kit and analyzed for purity using A260/280 readings. RNA purity for each sample was 1.7–1.9. Samples were analyzed using Affymetrix miRNA 1.0, allowing for analysis of 609 miRNA species. Target prediction was performed on microRNA.org Miranda and MirSvR databases and pathway analysis was performed using Ingenuity Pathway Analysis [IPA] Software. miRNA differences were validated using Quant iTech Sybr Green PCR kit and miRNA primer assays [Qiagen].

**IL-10 neutralization**
Mice were sensitized to mBSA and treated with vehicle or AEA as described above. One hour after each treatment with AEA or vehicle, mice were given 50 µg monoclonal antibodies to IL-10 [JES5-16E3] or isotype control. Mice were rechallenged and footpads were measured as before.

**In vitro IL-10 treatment**
LN from mBSA-sensitized mice were prepared as before and plated in the presence of 40 µg/ml mBSA and increasing doses of IL-10 [10 or 20 ng/ml]. Cells were assayed for Th17 induction and miRNA profile as before.

**Real-Time PCR**
RNA was isolated from draining LN using the miRNAeasy RNA isolation kit [Qiagen]. cDNA synthesis was performed using iScript cDNA synthesis kit [Biorad]. All samples were run on a BioRad CXP96 Thermal Cycler.

**Statistical analysis**
All statistical analyses were performed using Graphpad Software. Swelling data were analyzed using the Mann-Whitney U test, while all other data were analyzed by either the Student’s t test or ANOVA, as appropriate.

**Results**

**AEA mitigates mBSA-induced inflammation**
The endogenous cannabinoid system is important for regulating the hypersensitivity response [10], although the precise mechanisms remain unclear. In the current study, we tested the effect AEA, an endocannabinoid, on mBSA-induced Type-IV hypersensitivity in mice, which is mediated primarily by IL-17-producing T cells [11]. To this end, we sensitized mice to mBSA and treated them with AEA or vehicle for two days prior to rechallenge. Each mouse was rechallenged in the right footpad with mBSA and in the left footpad with vehicle, as described in Methods. We found that AEA-treated mice had significantly less swelling index in mBSA rechallenged footpads than vehicle-treated mice [Fig 1A], indicative of decreased inflammation.
Furthermore, draining lymph nodes were taken and cells were counted to assess the lymph node cell proliferation in response to mBSA. Lymph node cells from AEA-treated mice showed decreased cell yield than vehicle-treated mice [Fig 1B], indicative of decreased response to mBSA. Next, we stained the lymph node cells for intracellular IL-17 by flow cytometry and calculated the absolute numbers of Th17 cells. mBSA immunization caused significant increase in IL-17 producing cells when compared to naïve mice, and AEA treatment significantly reduced the number of IL-17 producing cells [Fig 1C]. Histopathological analysis of footpads showed that mBSA treatment triggered strong infiltration of immune cells which was decreased following AEA treatment [Fig 2]. There was also less edema in AEA treated footpads. AEA effectively limited the disease manifestations of mBSA-induced hypersensitivity.

AEA treatment skews away from proinflammatory cytokine production

We next tested for cytokine production, specifically both pro- and anti-inflammatory, from draining LN cells of mBSA-immunized mice treated with AEA or vehicle. To that end, we sensitized mice to mBSA and treated them with AEA or vehicle as before. We sacrificed these mice 24 hours after restimulation with mBSA and plated draining LN cells in complete RPMI overnight to allow for spontaneous cytokine secretion and then measured the levels of cytokines by ELISA. We found that AEA treatment significantly reduced IL-17 [Fig 3A] and IFN-γ [Fig 3C] secretion, as well as reduced RORγt expression [Fig 3B]. We also found that AEA treated cells produced significantly more IL-10 than vehicle controls [Fig 3D]. These data suggested that AEA decreases the induction of proinflammatory cytokines such as IL-17 and IFN-γ and that this may result from increased IL-10 production.

AEA mediates decrease in mBSA-Hypersensitivity by IL-10 secretion

To directly test the role of IL-10, we sensitized mice to mBSA and treated them with AEA or vehicle as before. Next, we injected the mice with a neutralizing antibody to IL-10 [JES5-16E3] or isotype control antibody 1 hour after treatment with AEA or vehicle. We found that neutralizing IL-10 in vivo resulted in complete reversal of AEA-induced immunosuppression [Fig 4A]. Next, we cultured lymph node cells from mBSA-sensitized mice as before. We then treated those cells with increasing concentrations of IL-10 to test the ability for IL-10 to suppress mBSA-induced IL-17 production. IL-10 was able to decrease IL-17-producing cells in a dose dependent fashion [Fig 4B].

miRNA analysis of AEA treated mBSA mice

Recent studies have shown that microRNAs [miRNA] can regulate cytokines and inflammatory diseases [25-27]. To test if the immunosuppression by AEA was mediated by miRNA, we...
isolated total RNA from draining lymph nodes in mice sensitized to mBSA and treated with vehicle or AEA, as before. We analyzed those samples using Affymetrix miRNA 1.0 microarray. We analyzed 609 different miRNA species for changes in AEA treated mice compared to vehicle controls [Fig 5A]. We found that AEA showed a different expression pattern of miRNA species than vehicle-treated mice. Specifically, there were 100 miRNA species that were differentially regulated in AEA-treated animals, 55 upregulated 1.5 fold or greater and 45 downregulated 1.5 fold or greater [Fig 5B]. We next looked for the most differentially regulated miRNA species. We found that AEA highly upregulated the expression of miRNA 125a-5p [+3.35], miRNA 301a [+2.50], miRNA 30c [+2.57], miRNA 151 [+2.32], and many others. Conversely, AEA downregulated miRNA 374 [−2.38], miRNA 491 [−2.46], and miRNA 132 [−2.89], among others [Fig 5C]. Using Ingenuity Pathway Analysis, we found that AEA significantly affected several miRNA-regulated canonical biological pathways [Fig 5D]. Among these, Infection Disease, Cell Cycle, Cell Death and Survival, and the Cell-mediated Immune Response were of interest in our system.

Role of IL-10-induced miRNA in the regulation of inflammation

Because we noted that IL-10 plays a crucial role in the regulation of anti-inflammatory effects of AEA, we next determined if IL-10 treatment induces miRNA that can suppress inflammatory pathways. To this end, we isolated RNA from mBSA sensitized cells treated with vehicle or rIL-10 at 10 and 20 ng/ml and analyzed them for specific miRNA that we identified from our in vivo data which could potentially target inflammatory pathways [Fig 5C]. Interestingly, we found that IL-10 was able to induce the expression of miRNA 30e, 504, 125a, 301a, and 21 [Fig 6A]. It was noteworthy that several of these miRNAs such as 30e, 125a, and 301a had been found to be up-regulated in vivo upon AEA treatment [Fig 4C]. We then used Ingenuity pathway analysis to determine the effect of these miRNAs on pro-inflammatory mediators [Fig 6B]. Interestingly, these microRNAs were found to target several proinflammatory cytokines and their receptors, including IFN-γ, TNF-α, and TGF-β/IL-6 necessary for Th17 differentiation. Along with these, STAT-3 was also targeted by several of these miRNAs. Together, these data suggested that AEA may promote IL-10 induction which in turn may up-regulate certain miRNA that suppress inflammatory pathways.

Discussion

Our current study shows that when endogenous cannabinoids are given as a treatment they can attenuate Th17 cell-mediated inflammation and the subsequent mBSA-induced hypersensitivity. AEA treatment effectively limited measurable inflammatory parameters, including footpad swelling, draining LN cell proliferation, and histopathological cell infiltration and tissue injury. We found that treatment of AEA in vivo decreased the generation of proinflammatory IFN-γ and IL-17 producing cells, while increasing IL-10 production. The induction of IL-10 was found to be
Figure 3. AEA treatment induces IL-10 expression, while suppressing IL-17 and IFN-γ. DTH response against mBSA was induced as described in Fig 1. Cells from draining lymph nodes of mBSA-rechallenged mice were isolated and cultured overnight to allow for spontaneous cytokine secretion. The culture supernatants were then analyzed for IL-17 [A], IFN-γ [C], and IL-10 [D]. ELISA data are representative of 3 individual experiments with n = 3. [B] RNA was isolated from LN of mice treated with AEA or Vehicle to analyze the expression of RORγt by RT-PCR. PCR plot is representative of 3 individual experiments with n = 3. *p<0.05 **p<0.01 when compared to vehicle.

doi:10.1371/journal.pone.0093954.g003

Figure 4. AEA suppresses DTH through IL-10 secretion. [A] Mice were sensitized to mBSA and treated with Vehicle or AEA, as described in Fig 1. An IL-10 neutralizing antibody or isotype control was given i.p. 1 hour before each treatment with AEA or vehicle, and [A] footpad swelling was measured. Footpad swelling data are a combination of 2 individual experiments with n = 3 for Veh and n = 3 for AEA. One mouse was excluded in both AEA treated groups because it was unclearly labeled. [B] Cells were isolated from the LN of mice sensitized to mBSA, plated, and cultured as described in Fig 3. rIL-10 was added to these cultures at 10, 20, or 40 ng/ml to assess the ability for IL-10 to knockdown the mBSA-induced Th17 response. Cells were cultured for 24 hours, and in the last 4 hours of culture, the cells were stimulated with PMA, Ionomycin, and Golgi Plug. Cells were harvested and stained for IL-17+ CD4 T cells. Data are representative of 3 individual experiments with n = 3. *p<0.05.

doi:10.1371/journal.pone.0093954.g004
critical for AEA-induced attenuation of the hypersensitivity response inasmuch as blocking IL-10 reversed the suppression of hypersensitivity caused by AEA. Finally, we showed that IL-10 directly induced several different microRNAs that targeted proinflammatory cytokines. Interestingly, miRNA analysis of cells from mice treated with AEA showed significant alterations in several miRNAs, some of which correlated with in vitro induction following IL-10 exposure. These data together suggested AEA suppresses inflammation through induction of IL-10, which mediates its effect by triggering several microRNAs that target proinflammatory cytokine pathways. Our data suggest that miRNA regulation serves as a potential mechanistic link between IL-10 and reduction of IL-17 and other proinflammatory cytokines such as IFN-γ. This study opens several avenues toward understanding the role of the endocannabinoid system and miRNA in regulating the immune response. While we studied the proinflammatory cytokine-induced delayed hypersensitivity response in this study, it is not clear if endocannabinoids would affect other inflammatory markers such as Serum Amyloid A or C-Reactive Protein, markers for systemic inflammation, and additional studies are necessary to address this.

Studies from our laboratory and elsewhere have characterized cannabinoids as potent immunosuppressive agents [30–35]. Δ9-tetrahydrocannabinol has been shown to induce apoptosis in dendritic cells via NF-κB [30], induce apoptosis in splenocytes [31], and mediate a cytokine shift from Th1 to Th2 cytokines [32]. Cannabinoids also induce populations of immunosuppressive cells including myeloid derived suppressor cells [33] and regulatory T cells [34,35]. While the mechanism for exogenous cannabinoid-mediated immune suppression is well characterized, remarkably little has been reported about the mechanisms involved in the regulation of immune system by endocannabinoids.

Mice lacking both known cannabinoid receptors were shown to display enhanced cutaneous contact hypersensitivity [10]. In the same study, mice with increased levels of the AEA displayed reduced allergic responses in the skin. These results demonstrated a protective role of the endocannabinoids in contact hypersensitivity. Endogenous cannabinoids have been implicated as a
putative therapeutic modality in immunological disease [36,37]. AEA has been reported to induce apoptosis and inhibit proliferation in lymphocytes [38]. Furthermore, anandamide affects the secretion of Th1 cytokines in peripheral mononuclear cells [39]. Fatty Acid Amide Hydrolase [FAAH] is also down regulated in response to LPS in human lymphocytes, leading to an increase in AEA [40]. Activation of the endocannabinoid system modulates macrophage activity in coronary artery disease [41], as well as affecting dendritic cells [42]. However, to the best of our knowledge, no mechanism has been described that linked the endogenous cannabinoid system to regulation of Th17 driven inflammation.

IL-10 was first described as an inhibitory factor secreted by Th2 cells that inhibited the secretion of cytokines by Th1 cells [43]. Cannabinoids have been linked to increased expression of IL-10 [44,45]. Recently, IL-10 signaling has been shown to be important for inhibition of Th17 mediate inflammation as well [46]. However, the precise mechanisms of IL-10-mediated inhibition of Th1 and Th17 inflammation are not well understood. It is known that IL-10 induces Gata-3 transcription [47]. Gata-3 is well known to inhibit the differentiation of other T helper cell lineages [48]. Using Theiler virus model of MS, it was shown that AEA enhanced IL-10 production by microglia and suppressed IL-12p70 and IL-23 [49]. In the current study, we noted that neutralization of IL-10 in vivo, reversed the immunosuppressive effects of AEA.
thereby suggesting the critical role played by IL-10. Moreover, our studies showed that IL-10 may regulate its effect through induction of miRNA species.

microRNAs play a critical role in T helper cell differentiation [25–27]. Our studies show that IL-10 induces specific microRNA, including miRNA 21, 304, 301a, 30e, and 125a that target genes important for the induction of other T helper subsets. miRNA 21 has been linked to inflammation through a variety of mechanism. Upregulation of miRNA 21 targets IL-12 in anti-mycobacterial responses, leading to impaired T cell anti-mycobacterial responses [50], miRNA 21 is also found to target TNF-α, IL-1β, TGF-β, and IL-6R according to Ingenuity pathway analysis. IL-1β has been shown to be critical for the induction of a delayed-type hypersensitivity response to mBSA [51]. Furthermore, IL-1β has been shown to promote the secretion of IL-17a by the induction of IRF4 [52,53]. miRNA 504 is a relatively unknown species of microRNA, with no previous reports about its role in inflammation. Our IPA analysis suggested that miRNA 504 targets several important molecules, including T-bet and STAT-3. T-bet is the master regulator for Th1 differentiation [54], and drives the immune response toward a proinflammatory environment. This could be a potential mechanism through which IL-10 inhibits differentiation of Th1 lineage, by direct binding and inhibiting T-bet.

The Ingenuity pathway analysis showed a possible effect of AEA on cell cycle progression. This effect has been noted previously, as cannabinoids have been reported to affect the cell cycle in many different cell types. Cannabidiol [CBD] inhibits proliferation of MOG-specific T cells in a mouse model of MS [55]. Endocannabinoids have also been shown to have this ability; 2-AG inhibits the activation and proliferation of U87MG glioma cells in response to peptidoglycan [56]. AEA inhibits the proliferation of human prostate cancer cell lines by downregulating epidermal growth factor receptor [57]. These studies corroborate the role of cannabinoids in cell cycle/proliferation pathways as suggested by pathway analysis.

In summary, our studies show that treatment with endocannabinoids leads to an increased secretion of IL-10, which triggers miRNA that negatively target IL-17 and other proinflammatory pathways, thereby suppresses delayed type hypersensitivity response. These studies open the door for further examination of these miRNAs and their target genes to identify new therapeutic targets to treat Th17-driven autoimmunity, such as Multiple Sclerosis. These studies also suggest that endogenous cannabinoid system is one of the homeostatic mechanisms that the body employs to down-regulate immune response to foreign antigens as well as combat autoimmunity. Targeting of this system could yield valuable therapeutics in the future.

Acknowledgments

The authors would like to thank the National Institute on Drug Abuse in Bethesda, MD for providing the AEA for use in these experiments. Also, many thanks to Instrumentation Resource Facility for the histology and assistance with processing.

Author Contributions

Conceived and designed the experiments: ARJ PN MN. Performed the experiments: ARJ. Analyzed the data: ARJ PN MN. Contributed reagents/materials/analysis tools: ARJ PN MN. Wrote the paper: ARJ PN MN. Significant revision and editing of manuscript: PN MN.

References

1. Hegle VL, Nagarkatti PS, Nagarkatti M (2011) Role of Myeloid-derived Suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabinoid. PLoS One 6(4): e16281.
2. McKallip RJ, Nagarkatti M, Nagarkatti PS (2005) Δ9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response. J. Immunol 174:3281–3289.
3. Greiseniec WE, Turner H (2010) Immunoactive effects of cannabinoids: Considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. Int J Neuropharmacol 103(3):547–55.
4. Pandey R, Hegle VL, Nagarkatti M, Nagarkatti PS (2011) Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model. J Pharmacol Exp Ther 330(3): 819–823.
5. Nagarkatti P, Pandey R, Rieder SA, Hegle VL, Nagarkatti M (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1(7):1333–49.
6. De Petrocellis L, Cascio MG, Di Marzo V (2004) The Endocannabinoid System: A general view and latest additions. Br J Pharmacol 141(5): 765–74.
7. Mallat A, Teixeira-Clerc F, Lestratznaj S (2013) Cannabinoid Signaling and liver therapeutics. J. Hepatol 59(4): 891–6
8. Marquez L, Suarez J, Iglésias M, Bermúdez-Silva FJ, Rodriguez F, et al. (2009) Ulcerative Colitis induces changes on the expression of the endocannabinoid system in human colonic tissue. PLoS One 4(9): e6893.
9. Horvath B, Mukhopadhyay P, Hasko G, Pacher P (2012) The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am. J Pathol 180(2): 432–40.
10. Karakol M, Gaffal K, Dute R, Wang-Eckhardt L, Rehnel J, et al. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system in human skin. Science 316(5830): 1494–7.
11. Nakae S, Komiya Y, Nambu A, Sudo K, Iwase M, et al. (2002) Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17(3): 373–87.
12. Egan P, van Wijnenhuijze A, Campbell IK, Wicks IP (2008) Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum 50(12): 3720–9.
13. Sakai M, Yamashita K, Takemoto N, Ohshima Y, Tsukimoto M, et al. (2009) Diesel exhaust [DE] aggravates pathology of delayed-type hypersensitivity [DTH] induced by methyl-bovine serum albumin [mBSA] in mice. J Toxicol Sci 34(5): 463–92.
14. Samraut B, Jansson AH, Matusieviciene G, Scheyru A, Pierrou S, et al. (1999) N,N′-diacetyl-L-lysine-the dialdehyde dimer of N-acetylcysteine- is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther 290(3):1174–84.
15. Nakae S, Nambu A, Sudo K, Isokura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17 deficient mice. J Immunol 171(11): 6173–7.
16. Langrish CL, Chen Y, Blumenschein, Mattson J, Basham B, et al. (2005) IL-23 drives pathogenic T cell population that induces autoimmune inflammation. J Exp Med 205: 231–40.
17. Batten M, Iji Y, Si S, Klavjan NM, Danilenko DM, et al. (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7(9): 929–36.
18. Tajiri K, Shinjyo N, Sakai S, Machino-Ohtsuka T, Inamaka-Yoshida K, et al. (2013) Pitavastatin Regulates Helper T-Cell Differentiation and Ameliorates Autoimmune Myocarditis in Mice. Cardiocardio Drugs Ther 27(5): 413–24.
19. Mach C, Kim J, Soham B, Creighton CJ, Hawkins SM, et al. (2013) Novel MicroRNAs Regulating Proliferation and Apoptosis in Uterine Papillary Serous Carcinoma. Cancer Lett 335(2): 314–22.
20. Cai B, An Y, Lv N, Chen J, Tu M, et al. (2013) miRNA-101b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Onco. Rep 29(5): 1769–76
21. Wang L, Ji XJ, Jiang HJ, Du Y, Yang F, et al. (2013) MiRNA-185, MiRNA-96 and MiRNA-223 Repress Selective HDL-Cholesterol Uptake by Posttranscriptional Inhibition of Scavenger Receptor Class BII in Hepatic Cells. Mol Cell Biol 33(10): 1956–64.
22. Cao L, Kong LP, Yu ZB, Han SP, Bai YF, et al. (2012) microRNA expression profiling of the developing mouse heart. Int J Mol Med 30(5): 1093–104
23. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.
24. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854.
25. Guan H, Fan D, Mihalidou D, Hao H, Singh NP, et al. (2012) MicroRNA let-7e is associated with the pathogenesis of experimental autoimmune encephalomyelitis. Eur. J. Immunol 43(1): 104–114.
26. Yao R, Ma YL, Liang W, Li HH, Ma ZJ, et al. (2012) MicroRNA-155 modulates Treg and Th17 cell differentiation and Th17 cell function by targeting SOCS1. PLoS One 7(10):e46082.
27. Takahashi H, Kanno T, Nakayama S, Hirahara K, Sciume G, et al. (2012) TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constricts the plasticity of helper T. cells.

28. Solberg OD, Ostrin EJ, Love MH, Feng JC, Bhakta NR et al. (2012) Airway Epithelial microRNA Expression is Altered in Asthma. Am J Respir Crit Care Med 186(6):963–974.

29. Lu TX, Hartner J, Lim EJ, Fabry V, Mingler MK, et al. (2011) MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-γ Pathway, Th1 Polarization, and the Severity of Delayed-Type Hypersensitivity. J Immunol 187(6):3362–3373.

30. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS (2004) Activation through 29. Lu TX, Hartner J, Lim EJ, Fabry V, Mingler MK, et al. (2011) MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-γ Pathway, Th1 Polarization, and the Severity of Delayed-Type Hypersensitivity. J Immunol 187(6):3362–3373.

31. McKallip RJ, Lombar C, Martin BR, Nagarkatti M, Nagarkatti PS (2002). D

32. Newton CA, Lu T, Nazian SJ, Perkins I, Friedman H, et al. (2004) The THC-Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. Arch Biochem Biophys 393:321–28.

33. Hegde VL, Nagarkatti PS, Nagarkatti M (2011) Role of Myeloid-derived Suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One 6(4):e19291.

34. Hegde VL, Nagarkatti M, Nagarkatti PS (2010) Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol 40:3358–3371.

35. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, et al. (2008) Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol 74(1):20–33.

36. Pandey R, Mousavv K, Nagarkatti M, Nagarkatti P (2009) Endocannabinoids and immune regulation. Pharmacol Res 60(2):85–92.

37. Costola-de-Souza C, Ribeiro A, Ferraz-de-Paula V, Calefi AS, Aloia TP, et al. (2013) Monocacylglycerol Lipase inhibition attenuates acute Lung Injury in human malignant glioma cells. Oncol Rep 28(4):1176–80.

38. Schwartz H, Blanco JJ, Lotz M (1994) Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 55:107–115.

39. Berridge MV, Biochot E, Germain N, Allain N, Anger JP, et al. (1997) Influence of fatty acid ethanolamides and Δ9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330:231–40.

40. Maccarrone M, De Petrocellis L, Bari M, Fezza F, Salvati S, et al. (2001) Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases Anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 393:321–28.

41. Sugamura K, Sugiya S, Nocaki T, Matouzawa Y, Irumiya Y, et al. (2009) Activated Endocannabinoid System in Coronary Artery Disease and Antinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. Circulation 119:29–36.

42. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, et al. (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269:3771–8.

43. Fiorentino DF, Bond MW, Mosmann TR (1989) Th2 Clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170(6):2081–95.

44. Liu DZ, Hu CM, Huang CH, Wey SP, Jan TR (2010) Cannabinoids attenuates delayed-type hypersensitivity via suppressing T-cell and macrophage reactivity. Acta Pharmacol Sin 31(12):1611–7.

45. Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, et al. (2013) Cannabinoids decrease the Th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol Epub.

46. Chaudhury A, Samstein RM, Treuting P, Li Y, Pils MC, et al. (2011) Interleukin-10 signaling in Regulatory T Cells is Required for Suppression of Th17 Cell-Mediated Inflammation. Immunity 34:566–76.

47. Kosaka S, Tamauchi H, Terashima M, Murauma H, Habu S, et al. (2011) IL-10 controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation. Immunobiology 216(7):811–20.

48. Callard RE (2007) Decision-making by the immune response. Immuno Cell Biol 55(5):300–5.

49. Correa F, Hernangomez-Herrero M, Mestre L, Loria F, Docagne F, et al. (2011) The endocannabinoid Anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 25(4):736–49.

50. Wu Z, Lu H, Sheng J, Li I (2012) Inductive microRNA-21 impairs antimycobacterial responses by targeting IL-12 and Bcl-2. FEBS Lett 586(16):2459–67.

51. Nambu A, Nakae S, Ikokura Y (2006) IL-1β, but not IL-1α, is required for antigen specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity response. Int Immunol 18(3):701–12.

52. Lator SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, et al. (2011) Caspaesc-1-processed cytokines IL-1βeta and IL-10 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmune. J Immunol 186(10):5738–48.

53. Lee WW, Kang SW, Choi J, Lee SH, Shah K, et al. (2009) Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 113(5):530–40.

54. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, et al. (2000) A Novel transcription factor, T-bet, directs Th1 Lineage commitment. Cell 100(6):655–69.

55. Kozela E, Lev N, Kaushansky N, Elam R, Rimmerman N, et al. (2011) Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C37IL/6 mice. Br J Pharmacol 163(7):1507–19.

56. Echigo R, Sugimoto N, Yachie A, Ohno-Shosaku T (2012) Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells. Oncol Rep 28(4):1176–80.

57. Mienceult M, Pommery N, Wattez N, Bailly C, Henichart JP (2003) Antiproliferative and apoptotic effects of Anandamide in human prostate cancer cell lines: implications of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56(1):1–12.